Personalis (NASDAQ:PSNL) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Personalis (NASDAQ:PSNL) from a sell rating to a hold rating in a research report released on Sunday morning.

Several other equities research analysts have also recently commented on the company. Guggenheim boosted their target price on Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Morgan Stanley cut their price target on shares of Personalis from $11.00 to $10.00 and set an “equal weight” rating on the stock in a report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research report on Thursday, January 22nd. BTIG Research raised their price objective on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Finally, Needham & Company LLC lifted their price objective on shares of Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

Personalis Price Performance

NASDAQ PSNL opened at $7.84 on Friday. The business’s 50-day simple moving average is $8.85 and its 200-day simple moving average is $8.14. Personalis has a 1-year low of $2.83 and a 1-year high of $11.50. The firm has a market capitalization of $820.30 million, a P/E ratio of -8.62 and a beta of 2.02.

Personalis (NASDAQ:PSNL) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.05. Personalis had a negative net margin of 116.69% and a negative return on equity of 39.13%. The business had revenue of $17.35 million during the quarter, compared to analyst estimates of $17.12 million. On average, equities research analysts expect that Personalis will post -1.4 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd boosted its position in shares of Personalis by 76.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after acquiring an additional 1,479 shares in the last quarter. Deutsche Bank AG increased its holdings in Personalis by 4.5% in the 4th quarter. Deutsche Bank AG now owns 38,827 shares of the company’s stock worth $309,000 after purchasing an additional 1,655 shares in the last quarter. Royal Bank of Canada raised its holdings in Personalis by 3.2% in the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after buying an additional 2,395 shares during the last quarter. Howland Capital Management LLC grew its holdings in Personalis by 0.9% during the 2nd quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock worth $1,872,000 after acquiring an additional 2,500 shares during the last quarter. Finally, Intech Investment Management LLC grew its holdings in Personalis by 23.4% during the 4th quarter. Intech Investment Management LLC now owns 20,342 shares of the company’s stock worth $162,000 after acquiring an additional 3,851 shares during the last quarter. Institutional investors and hedge funds own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.